U.S., Oct. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07891572) titled 'Oxaliplatin-Based Adjuvant Therapy for Gastrointestinal Neuroendocrine Carcinoma**' on Sept. 15.
Brief Summary: Patients with pathologically-confirmed gastrointestinal neuroendocrine carcinoma will be enrolled, to explore the efficacy and safety of oxaliplatin-based doublet chemotherapy in the adjuvant treatment of gastrointestinal neuroendocrine carcinoma. For patients after radical resection, adjuvant chemotherapy is recommended. XELOX, SOX or FOLFOX regimens can be selected based on the patient's physical status. Single-agent chemotherapy alone is not recommended.
Study Start Date: Sept., 2026
Study Type: OBSERVATIONAL
Conditi...